Log In
Print this Print this

AT001, AT001/r84, r84

  Manage Alerts
Collapse Summary General Information
Company Affitech A/S
DescriptionHuman antibody that blocks binding of VEGF to VEGF-2
Molecular Target Vascular endothelial growth factor (VEGF) receptor
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner International Biotech Center Generium (IBC Generium); Peregrine Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today